Adults aged 18 to 75 years (inclusive) with a diagnosis of plaque psoriasis for 24 weeks or more, may qualify for this study. Qualified participants must also have moderate to severe disease with psoriatic plaques covering 10% or more body surface area. Individuals with a diagnosis of non-plaque psoriasis or drug-induced psoriasis, are not qualified for this study.
Participants will receive investigational oral medication (active study drug) or placebo. Study medication and study-related assessments will be provided at no cost.
Study participation will last about 24 weeks and involve about 9 visits to the study centre.